Amphotericin B (Amphotericin B) Patent Expiration, LOE Window & CMS Spending

Amphotericin B (Amphotericin B) by X-Gen Pharmaceu: Multi-Source Generic Molecule, 4 AB generics, $94K 2024 CMS Part D & Medicaid spend, and $239 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorX-Gen Pharmaceu
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$94K
2024 Medicare Part D Spend$22K
2024 Medicaid Spend$72K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($239 intro WAC)